Capital Fund Management (CFM)’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22.2M Sell
145,100
-32,300
-18% -$4.95M 0.1% 279
2025
Q4
$24.5M Buy
177,400
+99,600
+128% +$13M 0.07% 408
2025
Q3
$9.98M Sell
77,800
-59,100
-43% -$7.21M 0.03% 831
2025
Q2
$16.6M Sell
136,900
-18,400
-12% -$2.07M 0.05% 528
2025
Q1
$17.3M Buy
155,300
+87,500
+129% +$9.32M 0.05% 491
2024
Q4
$6.6M Buy
67,800
+52,300
+337% +$5.58M 0.02% 955
2024
Q3
$1.78M Sell
15,500
-700
-4% -$79.4K ﹤0.01% 1492
2024
Q2
$1.72M Sell
16,200
-8,700
-35% -$873K 0.01% 1443
2024
Q1
$2.41M Buy
24,900
+8,700
+54% +$892K 0.01% 1360
2023
Q4
$1.64M Buy
+16,200
New +$1.56M ﹤0.01% 1629
2023
Q1
Sell
-14,200
Closed -$1.29M 1689
2022
Q4
$1.29M Buy
+14,200
New +$1.2M 0.01% 1067
2020
Q2
Sell
-28,300
Closed -$2.33M 1400
2020
Q1
$2.33M Buy
+28,300
New +$2.52M 0.04% 481
2019
Q4
Sell
-3,200
Closed -$278K 1972
2019
Q3
$278K Sell
3,200
-1,400
-30% -$126K ﹤0.01% 1455
2019
Q2
$420K Buy
+4,600
New +$389K ﹤0.01% 1270
2019
Q1
Sell
-99,436
Closed -$7.65M 1972
2018
Q4
$7.65M Buy
+99,436
New +$7.74M 0.07% 383
2018
Q3
Sell
-6,250
Closed -$423K 2169
2018
Q2
$423K Buy
6,250
+1,786
+40% +$123K ﹤0.01% 1666
2018
Q1
$323K Buy
+4,464
New +$340K ﹤0.01% 1612
2017
Q4
Sell
-3,236
Closed -$249K 1932
2017
Q3
$249K Sell
3,236
-112
-3% -$8.46K ﹤0.01% 1376
2017
Q2
$250K Buy
+3,348
New +$237K ﹤0.01% 1331
2016
Q4
Sell
-4,018
Closed -$284K 1796
2016
Q3
$284K Sell
4,018
-2,566
-39% -$187K ﹤0.01% 1395
2016
Q2
$487K Buy
+6,584
New +$455K ﹤0.01% 1184
2016
Q1
Sell
-3,683
Closed -$284K 1752
2015
Q4
$284K Buy
+3,683
New +$293K ﹤0.01% 1334
2015
Q2
Sell
-2,455
Closed -$217K 1639
2015
Q1
$217K Sell
2,455
-2,679
-52% -$238K ﹤0.01% 1353
2014
Q4
$426K Hold
5,134
0.01% 1197
2014
Q3
$433K Buy
+5,134
New +$415K ﹤0.01% 1200

Other funds holding NVS

Capital Fund Management (CFM)'s NVS Position: Q2 2025 in Review

Capital Fund Management (CFM) sold out of Novartis (NVS) in Q2 2025, closing a stake of 11,177 shares — an estimated $1.26M sold.

Capital Fund Management (CFM) first reported a position in NVS in Q2 2013 and held it in 21 quarters. The position peaked at $29.2M in Q2 2018. 1,383 funds tracked by Wall St. Rank hold NVS as of Q2 2025.

  • Capital Fund Management (CFM) reported no remaining Novartis position as of Q2 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 11,177 Novartis shares in Q2 2025, an estimated $1.26M.
  • Capital Fund Management (CFM) first reported a position in Novartis in Q2 2013 and held it in 21 quarters.
  • Capital Fund Management (CFM)'s Novartis position peaked at $29.2M in Q2 2018.
  • 1,383 funds tracked by Wall St. Rank held Novartis as of Q2 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2025, filed 13 Aug 2025.